Researchers have found evidence that could help explain why some anemic CKD patients are resistant to treatment with erythropoiesis stimulating agents. Patients on high-dose ESA had significantly ...
Only about a quarter of patients who have myelodysplastic syndrome (MDS) experienced hematologic improvement with erythropoiesis-stimulating agents (ESAs). Patients with lower-risk myelodysplastic ...
A decade of globalization: Trends in participation of investigators from lower-resource economies in phase III lung cancer trials. Background: Two ESAs (darbepoetin alfa, epoetin alfa) are ...
Once-monthly dosing of Hematide safely boosted hemoglobin in non-dialysis anemic CKD patients. BARCELONA—A novel peptide-based erythropoiesis-stimulating agent (ESA) called Hematide safely raises ...
Please provide your email address to receive an email when new articles are posted on . Patients switched to oral vadadustat had hemoglobin levels similar to those on a long-acting ...
Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Well, for patients who are on dialysis, ...
Treatment with vadadustat was noninferior to darbepoetin alfa in correcting and maintaining Hb levels in adults with incident dialysis-dependent CKD. The Food and Drug Administration (FDA) has ...
A post-hoc analysis of the phase 3b JUMP trial assessed outcomes in patients with myelofibrosis and baseline anemia who were treated with ruxolitinib alongside anemia-supportive therapies, according ...
Allowable levels of lead in U.S. drinking water may still put Americans with kidney failure at risk for hematologic toxicity and lead poisoning, a cross-sectional analysis suggested. In fact, even ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback